PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

For example, the Framingham Heart Study focused on atrial fibrillation and HF and showed that 31% ... 5 Another important finding of their study is that radiofrequency ablation for the treatment of AA ...

Cite this: Progress in Paroxysmal Nocturnal Hemoglobinuria Treatment: The Impact of New Data From ASH 2024 - Medscape - Jan 02, 2025. Professor of Clinical Medicine, Jane Anne Nohl Division ...

We report the individual components of MACE+ and the individual rhythm disturbances contributing to the composite arrhythmia end point (ie, atrial fibrillation and other arrhythmias including ...

SEATTLE, Dec. 6, 2024 /PRNewswire/ -- The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive ...

It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe ...

In particular, the patients had recurrent episodes of paroxysmal atrial fibrillation ... ectopic atrial tachycardia from a single pulmonary vein. There were no serious complications in either group, ...

7 Rate control in combination with anticoagulation as front-line treatment has been shown ... Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med.